Sugi Predict

Sugi Predict / Compounds / SCHEMBL2018207

SCHEMBL2018207

SCHEMBL2018207

CCNc1c(N)cccc1Br

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.36
▸ GAA P10253 2/20 0.36
▸ MAPT P10636 2/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ ALDH1A1 P00352 4/20 0.35
▸ HPGD P15428 2/20 0.35
▸ THRB P10828 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ GFER P55789 1/20 0.35
▸ PLEC Q15149 1/20 0.35
▸ CYP3A4 P08684 2/20 0.34
▸ TSHR P16473 2/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ NOS3 P29474 2/20 0.32
▸ NOS1 P29475 2/20 0.32
▸ NOS2 P35228 2/20 0.32
▸ KCNH2 Q12809 1/20 0.32
▸ CACNA1C Q13936 1/20 0.32
▸ SCN5A Q14524 1/20 0.32
▸ GABRA1 P14867 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31204396 1.00 KDM4E (0.36) KDM4EGAAMAPTHSD17B10ALDH1A1
SCHEMBL8506532 0.85 CYP3A4 (0.42) KDM4EGAAMAPTHSD17B10ALDH1A1
SCHEMBL27245494 0.82 F2R (0.42) KDM4EGAAMAPTALDH1A1TDP1
SCHEMBL11662307 0.78 ALDH1A1 (0.44) GAAMAPTALDH1A1HTTCYP3A4
SCHEMBL13497804 0.78 CD44 (0.46) KDM4EGAAMAPTHSD17B10ALDH1A1
SCHEMBL3035099 0.77 EGFR (0.41) KDM4EGAAMAPTALDH1A1HPGD
SCHEMBL29799761 0.77 CYP3A4 (0.39) KDM4EMAPTHSD17B10ALDH1A1HPGD
SCHEMBL933021 0.77 CYP3A4 (0.39) KDM4EMAPTHSD17B10ALDH1A1HPGD
SCHEMBL31700787 0.77 PTGER4 (0.42) KDM4EGAAMAPTALDH1A1PDE10A
SCHEMBL11426654 0.76 SCN5A (0.50) THRBTSHRKCNH2CACNA1CSCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002473-A1 QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF ACCUTAR BIOTECHNOLOGY INC. (US) 2025-01-02 — — US disclosed
WO-2024259216-A1 QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF ACCUTAR BIOTECHNOLOGY, INC. (US) 2024-12-19 — — WO disclosed
EP-4271664-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-11-08 — — EP disclosed
CN-116867758-A IRAK degradation agents and uses thereof 凯麦拉医疗公司 2023-10-10 — — CN disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 — — WO disclosed
WO-2022147465-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2022-07-07 — — WO disclosed
WO-2011079087-A1 ENAC BLOCKERS GLAXO GROUP LIMITED (GB) 2011-06-30 — — WO disclosed
WO-2011079087-A1 ENAC BLOCKERS GLAXO GROUP LIMITED (GB) 2011-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002473-A1 QUINOXALINE DERIVED SULFONAMIDES WITH EGFR DEGRADATION ACTIVITIES AND THEIR USES THEREOF EGFR, ERBB2, ERBB4 KDM4E 3536/4885GAA 139/4885MAPT 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.